Showing results (291-300 of 383) with videos related to
Sort By:
Pageof 39
Pharmacology, Biochemistry, and Behavior|January 26, 2011
The effect of pictorial warnings on cigarette packages on attentional bias of smokersSabine Loeber, Sabine Vollstädt-Klein, Sophia Wilden, et al.The International Journal of Neuropsychopharmacology|January 6, 2010
Smoking behaviour is associated with expression and phosphorylation of CREB in human buffy coatBernd Lenz, Hans-Wolfgang Klafki, Thomas Hillemacher, et al.European Journal of Anaesthesiology|February 17, 2026
Dopaminergic sub-network connectivity alterations are associated with postoperative cognitive dysfunction: Results from the observational BioCog cohort studyFlorian Lammers-Lietz, Friedrich Borchers, Insa Feinkohl, et al.Pharmacopsychiatry|February 4, 2010
The tolerability of rTMS treatment in schizophrenia with respect to cognitive functionM Mittrach, J Thünker, G Winterer, et al.Current Pharmaceutical Biotechnology|January 31, 2012
DTNBP1 (dysbindin) gene variants: in vivo evidence for effects on hippocampal glutamate statusC Wirth, F Schubert, M Lautenschlager, et al.Journal of Magnetic Resonance Imaging : JMRI|November 21, 2012
A stress MRI of the shoulder for evaluation of ligamentous stabilizers in acute and chronic acromioclavicular joint instabilitiesKaywan Izadpanah, Jan Winterer, Marco Vicari, et al.BMC Geriatrics|July 3, 2025
A secondary analysis of cortical atrophy and plasma amyloid β patterns in older patients with cognitive frailty undergoing elective surgeryRudolf Mörgeli, Friedrich Borchers, Insa Feinkohl, et al.European Archives of Psychiatry and Clinical Neuroscience|January 8, 2022
Cortical thickness across the cingulate gyrus in schizophrenia and its association to illness duration and memory performanceJ-W Thielen, B W Müller, D-I Chang, et al.The European Journal of Neuroscience|February 21, 2024
An exploratory research report on brain mineralization in postoperative delirium and cognitive declineFlorian Lammers-Lietz, Friedrich Borchers, Insa Feinkohl, et al.International Clinical Psychopharmacology|September 13, 2001
A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's diseaseE Ruether, R Husmann, E Kinzler, et al.Pageof 39